Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Obesity
  Roux-en-y Gastric Bypass
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. =18 years who are deemed medically stable
  2. =18 months status-post RYGB
  3. BMI 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition
  4. BMI 30 kg/m2 or greater
  5. Regain of =10% of maximum total body weight loss (TBWL) post-RYGB
  6. Ability to provide informed consent before any trial-related activities
  7. Express willingness to follow protocol requirements

  
  

You may not be eligible for this study if the following are true:

• 1. BMI of >45 kg/m2
  2. Pregnancy at time of enrollment
  3. Intention of becoming pregnant or breast feeding in the next 12 months
  4. Females of childbearing potential who are not using adequate contraceptive methods
  5. Presence of acute psychiatric problems or immaturity which would compromise cooperation with the study protocol
  6. Known or suspected allergy to liraglutide or any product components
  7. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
  8. History of pancreatitis
  9. History of Type 1 DM (Diabetes Mellitus)
  10. History of previous bariatric surgery other than RYGB except h/o Laparoscopic Adjustable Gastric Band (LAGB) and band removal (no current band patients)
  11. >10 years status-post RYGB
  12. < 25% TBWL at post-RYGB weight nadir
  13. >50% post-operative TBWL at time of screening
  14. Simultaneous use of any weight loss medications
  15. Use of insulin at the time of enrollment
  16. Current use of any GLP-1 agonist medication (Saxenda, Victoza, Trulicity, Ozempic, etc.)
  17. Histoy of taking any GLP-1 agonist medication (Saxenda, Victoza, Trulicity, Ozempic, etc.)
  18. Participation in another ongoing clinical study
  19. Conditions that, in the opinion of the principal investigator, may jeopardize the patient’s well-being and/or the soundness of this clinical study